Insiders Trades
Dr. Martens plc Stock: price and insider trades · United Kingdom
1 insider bought €172k of shares over the last 90 days, the latest filed 16 Oct 2026.
Dr. Martens plc: what insiders have been doing
Dr. Martens plc, classified in the Luxury & Fashion sector, is a listed company. Its insiders report their share dealings to RNS (LSE). In the past year (18 October 2025 to 18 October 2026), 46 filings came from 5 insiders.
The flow runs one way only: 3 insiders bought (8 purchases totalling €659k) and nobody sold on the market. The totals exclude 2 filings filed without an amount. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The buyers include 1 board member, 1 finance chief and 1 chief executive. Biggest ticket of the year: €172k, bought by Ije Nwokorie and made public on 16 October 2026 (0.022% of market cap).
Within a 30-day window, 4 purchases overlapped with buying by a second insider. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. The last purchase on record was published on 16 October 2026, which is 1 day ago. Filings reach the RNS (LSE) feed a median of 2 days after the trade. The legal deadline for notifying a trade is three business days (UK MAR).
With 46 filings in twelve months, the company is more active than the median of 6 filings across the 831 companies we follow on the same exchange. Looking back to 2023, when coverage begins, insiders filed 22 purchases and 1 sale.
For comparison within the same market, see the insider buying recorded at CMC Markets plc. Every figure here comes from the filings published by RNS (LSE) and describes the past, not future prices; it is not investment advice.
Insider Decl.
134
Thresholds
n/a
Buy Volume
€2M
22 ops. · all time
Sell Volume
€55,023
1 ops. · all time
Who traded when
BuySaleIje Nwokorie11 buys
Giles Wilson4 buys
Robert Hanson2 buys
Since the insiders bought
- -2.0%Entry £0.71 · Close 16 Oct 2026 £0.69
- -2.0%Entry £0.71 · Close 16 Oct 2026 £0.69
- -11.6%Entry £0.78 · Close 16 Oct 2026 £0.69
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Dr. Martens plc Buy (bullish), based on 6 analysts. Average price target: £0.98.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 6,879 of 24,148 companies
62.3
score / 100
Value72
Quality52
FCF yld20%
Earn yld3.7%
EV/EBITDA8.2x
ROE6.5%
Gross mgn66%
Net mgn3.1%
Debt/EBITDA3.1x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2026FY ended March 2026 · cache
£0.68
Analyst consensus
6 analystsBuy
£0.65Target £0.98(+44%)£1.41
Income statement
Revenue£764.9M
Gross profit£506M66% margin
EBITDA£127.7M17% margin
Net income£23.8M3.1% margin
Valuation
PER (trailing)34.0x
PER (forward)1124.7x
P/Book179.9x
Beta0.27
Balance sheet & cash
Market cap£650.9M
Total debt£393.5M
Free Cash Flow£130.8M
Debt / Equity109%
Profitability & ownership
ROE6.5%
ROA5.1%
% insiders41.8%
% institutions41.2%
Last declaration on 16 October 2026
Declarations134 total
443,457 sharesOutside a trading venueISIN GB00BL6NGV24FCA-NSM:aa98a7f2-3ce1-45da-8f89-9ac009a8cc4b-0
Canonical exit: 14 Jan 2027 (T+90)
209,160 shares@ £0.69250.022% mcap18.3% of flowXLONISIN GB00BL6NGV24FCA-NSM:aa98a7f2-3ce1-45da-8f89-9ac009a8cc4b-1
Canonical exit: 14 Jan 2027 (T+90)
440 shares@ £0.680.0% of flow1. London Stock Exchange (XLON) 2. Outside of a trading venueISIN GB00BL6NGV24RNS:9822368-0
442 shares@ £0.680.1% of flow1. London Stock Exchange (XLON) 2. Outside of a trading venueISIN GB00BL6NGV24RNS:9822368-1
308 shares@ £0.6780.0000% mcap0.0% of flowLondon Stock Exchange (XLON)ISIN GB00BL6NGV24RNS:9813977-0
278 shares@ £0.6780.0000% mcap0.1% of flowLondon Stock Exchange (XLON)ISIN GB00BL6NGV24RNS:9813977-1
464 shares@ £0.32350.0000% mcap0.0% of flow1. London Stock Exchange (XLON) 2. Outside of a trading venueISIN GB00BL6NGV24FCA-NSM:1a1ac2ae-8c6d-43d3-9ac1-50ffe77fd17e-0
462 shares@ £0.32350.0000% mcap0.1% of flow1. London Stock Exchange (XLON) 2. Outside of a trading venueISIN GB00BL6NGV24FCA-NSM:1a1ac2ae-8c6d-43d3-9ac1-50ffe77fd17e-1
358 shares@ £0.41890.0000% mcap0.0% of flow1. London Stock Exchange (XLON) 2. Outside of a trading venueISIN GB00BL6NGV24FCA-NSM:37b11de2-191f-4669-b31a-227023629ca3-0
358 shares@ £0.41890.0000% mcap0.1% of flow1. London Stock Exchange (XLON) 2. Outside of a trading venueISIN GB00BL6NGV24FCA-NSM:37b11de2-191f-4669-b31a-227023629ca3-1
404 shares@ £0.37130.0000% mcap0.1% of flow1. London Stock Exchange (XLON) 2. Outside of a trading venueISIN GB00BL6NGV24RNS:9672919-1
404 shares@ £0.37130.0000% mcap0.0% of flow1. London Stock Exchange (XLON) 2. Outside of a trading venueISIN GB00BL6NGV24RNS:9672919-0
01. London Stock Exchange (XLON) 2. Outside of a trading venueISIN GB00BL6NGV24RNS:81f51376-e262-44fa-a229-43dd2eba7595-0
01. London Stock Exchange (XLON) 2. Outside of a trading venueISIN GB00BL6NGV24RNS:81f51376-e262-44fa-a229-43dd2eba7595-1
68,313 shares@ £0.7170.0059% mcap26.2% of flowLondon Stock Exchange (XLON)ISIN GB00BL6NGV24RNS:cb007bcf-1129-47fc-a1bf-bab8e4432846-1
Canonical exit: 23 Sept 2026 (T+90)
118,516 shares@ £0.7170.010% mcap12.9% of flowLondon Stock Exchange (XLON)ISIN GB00BL6NGV24RNS:cb007bcf-1129-47fc-a1bf-bab8e4432846-0
Canonical exit: 23 Sept 2026 (T+90)
404 shares@ £0.37180.1% of flow1. London Stock Exchange (XLON) 2. Outside of a trading venueISIN GB00BL6NGV24RNS:9620596-1
404 shares@ £0.37180.0% of flow1. London Stock Exchange (XLON) 2. Outside of a trading venueISIN GB00BL6NGV24RNS:9620596-0
01. London Stock Exchange (XLON) 2. Outside of a trading venueISIN GB00BL6NGV24RNS:edd7caa0-aaea-48b6-91bc-889e396db09b-0
01. London Stock Exchange (XLON) 2. Outside of a trading venueISIN GB00BL6NGV24RNS:edd7caa0-aaea-48b6-91bc-889e396db09b-1
2,732,653 sharesOutside of a trading venueISIN GB00BL6NGV24RNS:9597070-0
2,100,151 sharesOutside of a trading venueISIN GB00BL6NGV24RNS:9597070-1
2,732,653 sharesOutside of a trading venueISIN GB00BL6NGV24RNS:5d364cb5-c38d-4e06-9a7d-bb54230bc2f5-0
2,100,151 sharesOutside of a trading venueISIN GB00BL6NGV24RNS:5d364cb5-c38d-4e06-9a7d-bb54230bc2f5-1
466 shares@ £0.3240.0% of flow1. London Stock Exchange (XLON) 2. Outside of a trading venueISIN GB00BL6NGV24RNS:9568480-0
25 of 134 declarations
About Dr. Martens plc
Dr. Martens plc is an iconic British premium footwear company listed on the London Stock Exchange (FTSE 100/250/AIM) in the United Kingdom under ticker DOCS.L. The modern brand traces its commercial origin to the first 1460 boot, launched on 1 April 1960 in Wollaston, England. Its roots, however, go back to post-war air-cushioned sole technology developed by Dr. Klaus Maertens. Over time, the brand evolved from a practical work boot into a globally recognised symbol of self-expression, durability and youth culture. The company’s head office is in London, and it operates through three regional hubs: EMEA, Americas and APAC, with a broad commercial footprint across Europe, North America and Asia-Pacific.
Dr. Martens’ business model is built around a small number of highly distinctive product families. The core offer includes the 1460 8-eye boot, the 1461 3-eye shoe, the 2976 Chelsea boot, and a growing assortment of shoes, sandals, mules, bags and accessories. The brand’s visual identity is exceptionally strong: yellow welt stitching, grooved soles and the black-and-yellow heel loop make the products instantly recognisable. This gives the group a durable competitive position in premium footwear, where it competes less on volume and more on brand equity, cultural relevance and product consistency. It serves customers through both direct-to-consumer and wholesale channels, enabling it to balance reach, control and merchandising flexibility.
Read moreShow less
Geographically, the United Kingdom remains the brand’s historic home, but Dr. Martens now operates as a global consumer brand with localised commercial execution in major markets. Its portfolio has remained anchored in iconic products, while management has continued to push extensions into adjacent categories where the brand DNA can travel credibly. Recent public updates released via RNS on the London Stock Exchange have included routine Director/PDMR shareholding notifications, holding disclosures and trading updates, which highlight the company’s active market communications and compliance with listed-company reporting standards. Recent messaging has also emphasised brand-led growth, operational discipline and execution against a refined strategy following a period of business stabilisation and leadership transition.
For investors, Dr. Martens offers exposure to a differentiated premium footwear franchise with strong heritage, global awareness and multi-category upside. At the same time, it remains sensitive to demand trends in discretionary spending, fashion cycles, channel mix and execution quality across its international retail and wholesale network.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
